Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Switch Study in CML-CP Patients with Imatinib Toxicity
NCT01660906Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2012
- Primary completion
- Oct 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 4 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Dec 2012; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01660906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01660906.